Listen: Matt Cable, Novartis, Co Valence discussed on The Kevin Rose Show
"But the point is that that manic paper in December of actually. We're coming up to almost four years since it came out summer two thousand fourteen you know, that paper was like the moment, I became obsessed with rapamycin, you know, prior to that I was super interested, and then I became obsessed because that said to me that the one thing I'm most afraid of seems to not be the case under certain conditions. Now, the other thing that people would tend to be afraid of which actually goes back to your question, by the way, m tour can organize itself in two ways. It can organize itself around a protein called raptor. Then if it does that it's called 'em Tor complex one. And it can also organize itself on a protein called Richter. And if it does that it's called 'em tour complex to. It seems that most of the longevity benefits happen when you inhibit 'em tour complex one, but not m tour complex to and you say organize itself around what do you mean by that? Exact meaning like these protein there is more than one protein in their sort of like, you know, confirmation Li like bound to each other. So they're not in co Valence bound to each other that meaning they don't have like super strong concrete bonds holding them, but they sort of wrap around each other. I say, and what tends to happen is like, you know, a molecule I can amino acid, for example, will hit one piece of it. And then that will trigger the movement, a come what we call a confirmational change in another piece, and then that will kick off a signal that goes, you know, down down the path when it's this inhibition of emperor complex to that. Also seems to produce some of the other unintended consequences of rapamycin, which by the way, there's some debate about. So most people would say, well, the other drawback rapamycin is it creates insulin resistance, you know, these pay. Patients that were put on rapamycin seemed to have a higher incidence of diabetes, and Matt cable, and who I would consider sort of probably one of the certainly two to three people that I think knows more about rapamycin than anybody in the world. You know, Matt has always call that into question, then he's made a good point. Which is if everything we think, we know about rapamycin is based on the transplant patients were we don't know that much right? Because those patients have a lot of other issues going on, and they're never just on rapamycin there on rapamycin and glucocorticoid 's an M F Flynn higher doses to right? Yes. And of course, they're taking them, you know, volley daily at higher levels. So so we also have to sort of say, maybe we're starting from scratch your like, maybe we really don't understand in in humans how to dose this meaning in dose or frequency to produce result. But in theory, what you would wanna do is inhibit 'em Tor complex one without inhibiting him toward complex too. So what is the result when that happens like in rodents and now, and if they seen any results in humans. Like restore bio, which is this company that I and I I know nothing about this company. I'm not involved in any way. So I just know what sort of publicly available, and they are public company. So I've seen their presentations, and you know, all the stuff that they presented during their IPO. I was followed that with interest. They are using something called ever alignments, which as I said is basically rapamycin in. I can't quite tell. But I think they're also combining it with another class of drug called a PI three kindness. And they're replicating the work that Novartis did so Joan manic who led the work at Novartis now at restore bio and they're going after different indications. So you except if if you're going down the path of drug development, you have to have an indication and longevity turns out to be really bad indication 'cause aging is not a disease. So it's hard to develop a drug that treats something that is not a disease, and Secondly, that's a really high bar to clear takes a long time to show that a drug can make you live longer.."